Migraine Disorders

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11        DESCRIPTION</h1>The active ingredient of QULIPTA is atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of atogepant is (3'S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide, and it has the following structural formula:<img alt="The active ingredient of TRADENAME is atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of atogepant is (S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide and has the following structural formula:" src="qulipta-01.jpg"/>The molecular formula is C29H23F6N5O3 and molecular weight is 603.5. Atogepant is a white to off-white powder. It is freely soluble in ethanol, soluble in methanol, sparingly soluble in acetone, slightly soluble in acetonitrile, and practically insoluble in water.QULIPTA is available as tablets for oral administration containing 10 mg, 30 mg, or 60 mg atogepant. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.</section>

Qulipta

atogepant

atogepant 10 MG Oral Tablet

atogepant 10 MG Oral Tablet [Qulipta]

atogepant 30 MG Oral Tablet

atogepant 30 MG Oral Tablet [Qulipta]

atogepant 60 MG Oral Tablet

atogepant 60 MG Oral Tablet [Qulipta]

Migraine with Aura

Migraine without Aura

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><h1>11        DESCRIPTION</h1>The active ingredient of UBRELVY is ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of ubrogepant is (3'S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide and has the following structural formula:<img alt="The following structural formula for UBRELVY is ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of ubrogepant is (3'S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide." src="ubrelvy-01.jpg"/>The molecular formula is C29H26F3N5O3 and molecular weight is 549.6. Ubrogepant is a white to off-white powder. It is freely soluble in ethanol, methanol, acetone, and acetonitrile; and is practically insoluble in water.UBRELVY is available as tablets for oral administration containing 50 mg or 100 mg ubrogepant. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.</section>

UBRELVY

Ubrelvy

ubrogepant

ubrogepant 100 MG Oral Tablet

ubrogepant 100 MG Oral Tablet [Ubrelvy]

ubrogepant 50 MG Oral Tablet

ubrogepant 50 MG Oral Tablet [Ubrelvy]

Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are fatigue, nausea, and constipation. 

Qulipta is FDA approved for the following indications: Migraine prevention.


Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Sample Online Form 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

Enroll in Patient Savings Program 

Abbvie Assist Patient Assistance Program Income Criteria & Eligibility 

Mechanism of Action (MOA)

Efficacy: 12-Week 

Efficacy: Patient Response 

Safety Profile: 52-Week 

Safety Profile: 12-Week 

Dosing 

Other HCP Resources 

About Qulipta 

Patient Stories 

Qulipta Complete Support Progam 

FAQs: Migraine Prevention 

Doctor Discussion Guide 

Instructions For Use: Migraine Prevention 

Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood vessel dilation, and inflammation. Ubrelvy is well-tolerated, with less than 5% of individuals reporting side effects such as nausea, somnolence, and dry mouth. Ubrelvy does not prevent migraines.

Ubrelvy is FDA approved for the following indications: Migraine. 


Qulipta®(atogepant)	Ubrelvy®(ubrogepant)

Prescription Only Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are...	Prescription Only Ubrelvy is a medication that adults can use to treat acute migraine attacks. It works by blocking CGRP, a protein believed to contribute to migraine attacks by causing pain, blood...
Dosage & Administration
Administration
Oral. Learn more.	Oral. Learn more.
Dosing
10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.. Learn more.	50 mg or 100 mg as needed. Maximum daily dose: 200 mg. Severe Hepatic or Severe Renal Impairment: 50 mg.. Learn more.
Latin Shorthand
10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd. Learn more.	50 mg PRN or 100 mg PRN. Severe Renal Impairment: 50mg.. Learn more.
Adverse Reactions
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.. Learn more.	The most common adverse reactions (at least 2% and greater than placebo) were nausea and somnolence.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
$0. Learn more.	$0. Learn more.
Annual Cap
$6000. Learn more.	Maximum savings of $50 per pill for up to 13 prescription fills.. Learn more.
Assistance Expiration
12 30-day prescription fills. Learn more.	13 prescription fills. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available

Qulipta® Alternatives